An Overview of the Patient Journey and Treatment Utilization in Patients With Prurigo Nodularis
Author(s)
William Ye, PharmD1, Xiaoxia Wang, PharmD1, Karishma Thakkar, PharmD, MS1, Da Sol Kim, PharmD, MS1, Tim Reynolds, PharmD, MS1, Linda Chen, PharmD, MS1, Erik Schindler, Pharm.D., BCPS2, Donia Bahloul, PharmD, MSc3, Paul Godley, PharmD, FASHP1;
1Baylor Scott & White Health, Temple, TX, USA, 2Sanofi, Cambridge, MA, USA, 3Sanofi, Gentilly, France
1Baylor Scott & White Health, Temple, TX, USA, 2Sanofi, Cambridge, MA, USA, 3Sanofi, Gentilly, France
OBJECTIVES: Prurigo nodularis (PN) is a low-prevalence skin disease characterized by intense pruritus and hyperkeratotic nodules symmetrically distributed on the extremities and trunk. There are currently no standardized guidelines for the management of PN. Given recent additions to the treatment armamentarium, it is crucial to understand the patient journey holistically to better inform stakeholders and ensure patients are receiving appropriate and timely therapy.
METHODS: In this retrospective descriptive analysis, de-identified data from electronic health records at a large integrated delivery network were utilized. Eligible patients were ≥18 years old, had ≥1 outpatient encounter with a primary diagnosis of PN between 1/1/2018 and 12/31/2021, and ≥1 additional outpatient encounter in the 12 months prior to and after the first encounter with a diagnosis of PN (index date). Patient characteristics, comorbidities, healthcare resource utilization (HCRU), and prescribing patterns were analyzed and compared between the 12 months (baseline) before and ≥12 months (follow-up) after the index date.
RESULTS: Overall, 2820 PN patients were identified. Patients had a mean age of 63.3 (±14.7) years, were mostly White (87.0%), and almost half of patients were female (49.0%). The average follow-up time was 3.15 years. Allergic rhinitis, asthma, and chronic pruritus of unknown origin were the most common atopic comorbidities. The proportion of patients having a dermatology visit increased from 45.6% (baseline) to 64.4% (follow-up). Seventy-three percent of patients had a prescription for any PN-related therapy, and 35.0% received a prescription for systemic therapy. Of those patients receiving treatment, topical steroids and gabapentinoids were the most common therapies prescribed as first or second line.
CONCLUSIONS: PN is a chronic, pruritic inflammatory skin disease with high disease burden. Evaluation of real-world prescription patterns suggest that the majority of patients are treated with topical and/or adjunctive therapies. Further research should assess evolving HCRU patterns as the PN treatment armamentarium expands.
METHODS: In this retrospective descriptive analysis, de-identified data from electronic health records at a large integrated delivery network were utilized. Eligible patients were ≥18 years old, had ≥1 outpatient encounter with a primary diagnosis of PN between 1/1/2018 and 12/31/2021, and ≥1 additional outpatient encounter in the 12 months prior to and after the first encounter with a diagnosis of PN (index date). Patient characteristics, comorbidities, healthcare resource utilization (HCRU), and prescribing patterns were analyzed and compared between the 12 months (baseline) before and ≥12 months (follow-up) after the index date.
RESULTS: Overall, 2820 PN patients were identified. Patients had a mean age of 63.3 (±14.7) years, were mostly White (87.0%), and almost half of patients were female (49.0%). The average follow-up time was 3.15 years. Allergic rhinitis, asthma, and chronic pruritus of unknown origin were the most common atopic comorbidities. The proportion of patients having a dermatology visit increased from 45.6% (baseline) to 64.4% (follow-up). Seventy-three percent of patients had a prescription for any PN-related therapy, and 35.0% received a prescription for systemic therapy. Of those patients receiving treatment, topical steroids and gabapentinoids were the most common therapies prescribed as first or second line.
CONCLUSIONS: PN is a chronic, pruritic inflammatory skin disease with high disease burden. Evaluation of real-world prescription patterns suggest that the majority of patients are treated with topical and/or adjunctive therapies. Further research should assess evolving HCRU patterns as the PN treatment armamentarium expands.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR48
Topic
Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives, Patient Engagement
Disease
SDC: Sensory System Disorders (Ear, Eye, Dental, Skin)